Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2001

View Archived Issues

Valentis highlights significant events over past year

Innogenetics updates product pipeline

FDA approves TAP's Spectracef

Devgen and Metabolex work together in the area of diabetes

U.S. Ethyol rights to be returned to MedImmune by October 1, 2001

deCODE locates genes linked to obesity and anxiety in a collaboration with Roche

ATL-193 and ATL-146e as pharmacological stress agents for myocardial perfusion imaging

Non-nucleoside-containing tricyclic platelet P2Y12 receptor antagonist characterized

Thirty-six-week follow-up data show maintenance of weight loss after treatment with Axokine

Potential new drug for removing cholesterol licensed to Samaritan

AERx iDMS showcased at EASD meeting

Men with diabetes-related ED respond well to on-demand treatment with IC-351

Oncolytics Biotech continues to make progress with reovirus as cancer therapy

Ferrochloroquine: high antimalarial activity coupled with lack of significant crossresistance

Procyon highlights Q2 developments

Fourth human beta-defensin peptide identified and characterized

Norwegian collaboration focuses on human antibodies for infectious diseases

PhotoCure prepares for Metvix launch; Hexvix development progressing as planned

Enrollment completed in pivotal Alzheimer's disease trial of Neotrofin

Myriad Genetics highlights development progress

Adapalene and pharmaceutical compositions thereof for use in cancer therapy

New ribozyme modulates CHK1 gene expression

Spiro protein farnesyltransferase inhibitors designed by Merck scientists

Novel PDE4 and TNF-alpha inhibitors in the Pfizer pipeline

Recent patent covers hydroxamic acid-based inhibitors of sCD23

Merck Frosst/AxyS collaboration identifies new cathepsin inhibitors

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...